SEC 13F Intelligence

Managers / Q1 2026

Ally Bridge Group (NY) LLC

CIK 0001822947 · 430 PARK AVENUE, 12TH FLOOR, NEW YORK, NY, 10022 · 6468299830

Reported Value
$124M
Q1 2026
Positions
28
Filings on Record
22
2019–present window
Filed
May 18, 2026
original filing

Summary

Ally Bridge Group (Ny) LLC reported $124M in U.S.-listed holdings across 28 positions for Q1 2026.

Its largest position, PRAX, represents 8.5% of the portfolio.

Compared with Q4 2025, the fund opened 12 new positions and exited 2.

Portfolio Metrics

Turnover
+34.9%
vs prior filed quarter
Top-10 Concentration
+53.0%
share of reported value
Largest Position
+8.5%
Praxis Precision Medicines I
New / Exited
12 / 2
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $584MQ4 ’20Q1 ’21: $522MQ2 ’21: $403MQ3 ’21: $340MQ3 ’21Q4 ’21: $286MQ1 ’22: $135MQ2 ’22: $110MQ2 ’22Q3 ’22: $151MQ4 ’22: $103MQ1 ’23: $76MQ1 ’23Q2 ’23: $83MQ3 ’23: $85MQ4 ’23: $168MQ4 ’23Q1 ’24: $180MQ2 ’24: $168MQ3 ’24: $187MQ3 ’24Q4 ’24: $117MQ1 ’25: $111MQ2 ’25: $120MQ2 ’25Q3 ’25: $164MQ4 ’25: $96MQ1 ’26: $124MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 82.1%ADR: 11.0%Other: 6.9%
  • Common Stock · 82.1% · $102M
  • ADR · 11.0% · $14M
  • Other · 6.9% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
TARSTARSUS PHARMACEUTICALS INCNEW+80.9K80.9K+$6M$6M
CMPXCOMPASS THERAPEUTICS INCNEW+1.00M1.00M+$5M$5M
CTMXCYTOMX THERAPEUTICS INC.NEW+900.0K900.0K+$4M$4M
CATXPERSPECTIVE THERAPEUTICS INCNEW+926.6K926.6K+$4M$4M
ALMSALUMIS INCNEW+167.0K167.0K+$4M$4M
UROGEN PHARMA LTDNEW+202.1K202.1K+$4M$4M
CAPRCAPRICOR THERAPEUTICS INCNEW+113.9K113.9K+$3M$3M
MAZEMAZE THERAPEUTICS INCNEW+100.0K100.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

21 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1PRAXPRAXIS PRECISION MEDICINES Ihistory →COM NEW8.54%$11M32.8K
2NERVMINERVA NEUROSCIENCES INChistory →COM NEW8.06%$10M1.66M
3SLNOEURSOLENO THERAPEUTICS INChistory →COM5.41%$7M200.0K
4OVIDOVID THERAPEUTICS INChistory →COM5.05%$6M2.82M
5CMPSCOMPASS PATHWAYS PLChistory →SPONSORED ADS4.67%$6M1.04M
6TARSTARSUS PHARMACEUTICALS INChistory →COM4.58%$6M80.9K
7SLDBSOLID BIOSCIENCES INChistory →COM NEW4.46%$6M767.0K
8PMNPROMIS NEUROSCIENCES INChistory →COM SHS4.25%$5M414.2K
9EWTXEDGEWISE THERAPEUTICS INChistory →COM4.10%$5M161.0K
10EPRXEUPRAXIA PHARMACEUTICALS INChistory →COM3.86%$5M660.4K
11CTMXCYTOMX THERAPEUTICS INC.history →COM3.42%$4M900.0K
12IVAINVENTIVA SAhistory →ADS3.34%$4M745.3K
13CATXPERSPECTIVE THERAPEUTICS INChistory →COM NEW3.12%$4M926.6K
14ABVXABIVAX SAhistory →SPONSORED ADS3.03%$4M33.7K
15ALMSALUMIS INChistory →COM2.97%$4M167.0K
16UROGEN PHARMA LTDCOM2.94%$4M202.1K
17CAPRCAPRICOR THERAPEUTICS INChistory →COM NEW2.80%$3M113.9K
18WHWKWHITEHAWK THERAPEUTICS INChistory →COM2.28%$3M817.9K
19IKTINHIBIKASE THERAPEUTICS INChistory →COM NEW1.80%$2M1.32M
20ANTXAN2 THERAPEUTICS INChistory →COM1.45%$2M526.3K
21RLMDRELMADA THERAPEUTICS INChistory →COM1.18%$1M210.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$124M28May 18, 202613F-HRchanges · EDGAR ↗
Q4 2025$96M20Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$164M25Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$120M24Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$111M28May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$117M30Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$187M29Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$168M25Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$180M22May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$168M22Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$85M19Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$83M17Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$76M18May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$103M30Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$151M39Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$110M22Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$135M21May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$286M30Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$340M31Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$403M29Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$522M32May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$584M30Feb 16, 202113F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • Fan Yu028-20833

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.